Trials / Recruiting
RecruitingNCT06041893
Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Haploidentical Hematopoietic Stem Cell Transplantation With Early Antithymocyte Globulin and Low Dose Post-transplant Cyclophosphamide
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Aim of this study is to investigate the effect of early administration of anti-thymocyte globulin and post-transplant low-dose cyclophosphamide in heploidentical hematopoietic stem cell transplantation.
Detailed description
Hematopoietic stem cell transplantation from a haploidentical donor (haplo-HCT) are increasingly used in patients lacking a matched donor, but the optimal strategy needs to be defined. This study aims to investigate the outcome of haplo-HCT with early antithymocyte globulin and low dose posttransplant cyclophosphamide (ATG/LD-PTCy) in a single center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATG-LDPTCy | antithymocyte globulin with low dose post-transplant cyclophosphamide |
Timeline
- Start date
- 2023-05-29
- Primary completion
- 2025-07-05
- Completion
- 2025-12-31
- First posted
- 2023-09-18
- Last updated
- 2024-12-03
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06041893. Inclusion in this directory is not an endorsement.